HCW Biologics restates Q1 EPS, cutting net income attributable to common shareholders by USD 728,000

Reuters2026/08/14 19:12

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

HCW Biologics filed restated quarterly results for the three months ended March 31, 2026 in a Form 10-Q/A.
Restatement corrected earnings-per-share under ASC 260, treating certain common warrants as participating securities under the two-class method.
Net income attributable to common stockholders fell by about USD 728,000 to USD 1.26 million.
Basic and diluted EPS dropped by USD 0.8 to USD 1.39, reflecting a one-for-six reverse stock split effective June 30, 2026.
Total net income stayed USD 3.47 million; cash flows, assets, liabilities, and equity were unchanged since the adjustment only reallocated earnings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-038246), on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

HCW Biologics restates Q1 EPS, cutting net income attributable to common shareholders by USD 728,000

You may also like

Crypto prices